New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Asklepios Kliniken · ISIN: DE000A0ETLQ3 · EQS - Company News (29 News)
Country: Germany · Primary market: Germany · EQS NID: 2023065
06 November 2024 10:00AM

Asklepios places its first Social Schuldschein loan of EUR 500.0 million


EQS-News: Asklepios Kliniken / Key word(s): Financing
Asklepios places its first Social Schuldschein loan of EUR 500.0 million

06.11.2024 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Asklepios places its first Social Schuldschein loan of EUR 500.0 million

  • First transaction under the newly established Social Finance Framework
  • Issuance proceeds to be used for (re-)financing social projects
  • High demand for the Social Schuldschein loan enabled a doubling of the issuance volume

Hamburg, November 6, 2024. Asklepios Kliniken GmbH & Co. KGaA successfully refinanced itself through a Social Schuldschein loan issuance amounting to EUR 500.0 million. The new Schuldschein was placed with maturities of 3, 5, 7, and 10 years among both existing and new investors.

The structure as a Social Schuldschein loan, through which the issuance proceeds under the newly established Social Finance Framework can be allocated to the area of social healthcare infrastructure, met with significant investor interest. Despite challenging market conditions, the issuance volume was doubled from the initial EUR 250.0 million to a total of EUR 500.0 million.

In addition to the official Schulschein marketing, existing investors with maturities in 2025 had the opportunity to reinvest their Schuldschein holdings early in the new Social Schuldschein through an exchange offer.

“The new Social Schuldschein loan enables us to finance investments in our healthcare infrastructure, thus ensuring a clear allocation of funds to the social benefit of our daily actions as a healthcare group,” says Hafid Rifi, Chief Financial Officer of the Asklepios Group. "Moreover, establishing the Asklepios Social Finance Framework marks an important step in further integrating our sustainability ambitions into our financing strategy," Rifi continues. "We are pleased with the strong demand from both existing and new investors, underscoring trust in our business model and corporate strategy once again."

“With 35% of the issuance volume, the share of foreign investors was high once again,” adds Benedikt Brörmann, Group Head of Corporate Finance & Treasury at Asklepios. "We were also able to place approximately 20% of the issuance volume with new investors," says Brörmann. “The success of this year’s transaction was due to the compelling Asklepios credit story combined with the right marketing strategy and timing.”

The placement of the Social Schuldschein loan was supported by Landesbank Hessen-Thüringen, ING Bank, Landesbank Baden-Württemberg, and UniCredit as arrangers. Linklaters LLP acted as Asklepios' legal advisor.

About Asklepios

Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients with a clear commitment to medical quality, innovation and social responsibility. On the basis of this, Asklepios has developed dynamically since it was founded more than 35 years ago. The group currently has 164 healthcare facilities across Germany. These include acute hospitals at all levels of care, university hospitals, specialist clinics, psychiatric and forensic facilities, rehabilitation clinics, care homes and medical centres. In the financial year 2023, over 3.5 million patients were treated in Asklepios Group facilities. The company has more than 68,000 employees.

 For inquiries:

Creditor Relations contact:
Stefan Sinzel
Manager Corporate Finance
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3 – 61462 Königstein-Falkenstein
Tel: +49 6174 9011-96
E-Mail: ir@asklepios.com

Press contact:
Rune Hoffmann
Head of Corporate Communications & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226 – 22307 Hamburg
Tel.: +49 40 1818-82 6630
Fax: +49 40 1818-82 6639
E-Mail: presse@asklepios.com

Visit Asklepios on the internet, Facebook, or YouTube:
www.asklepios.com
www.asklepios.com/konzern/gesundheitsmagazin
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken

Subscribe to the Asklepios newsletter:
https://www.asklepios.com/konzern/newsletter-anmeldung/
Nursing Blog: „Wir sind Pflege



06.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


2023065  06.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2023065&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.